Possible Interaction: Fluoxetine and Yohimbine

“The addition of the α2-antagonist yohimbine to fluoxetine appears to hasten the antidepressant response.”

“At the doses and treatments used, fluoxetine and bupropion did not alter locomotor activity or disturb the length of the estrous cycle; however, yohimbine inhibited locomotor activity.”

“However, in contrast to the selective α2‐AR antagonist, fluparoxan, the 5‐HT1A agonist actions of yohimbine suppress 5‐HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5‐HT levels.”

“In conclusion, the α2‐AR antagonist properties of yohimbine increase DA and NAD levels both alone and in association with fluoxetine.”

“ Yohimbine likewise facilitates the influence of fluoxetine upon DA and NAD levels, but not those of 5‐HT.”

“Fluoxetine (a selective serotonin reuptake inhibitor) treatment in rats reduced the immobility time, and pretreatment with yohimbine significantly enhanced the antidepressant-like behavior of fluoxetine at 5, 10 and 20 mg/kg.”

“Daily treatment with the combination of fluoxetine and yohimbine produced a significantly greater reduction in water intake than fluoxetine alone.”

“Additionally, drugs used to treat antidepressant-induced sexual dysfunction in the clinic, such as sildenafil, yohimbine , and dopamine agonists, were also effective in attenuating the deficits in the number of noncontact PE produced by chronic fluoxetine treatment.”

“Pretreatment with a muscarinic receptor antagonist, atropine (2 and 5 mg/kg, i.p) and an opioid … antagonist, naloxone (2 and 5 mg/kg, i.p), but not the alpha(2)-adrenoreceptor antagonist, yohimbine (2 and 5 mg/kg, i.…) reversed the antinociceptive effect of fluoxetine (20 mg/kg).”

“Dothiepin and mianserin (16 and 32 mg/kg), fluoxetine (32 and 64 mg/kg), maprotiline and imipramine (16, 32 and 64 mg/kg) and viloxazine (16 mg/kg) significantly potentiated mortality following acute administration with yohimbine.”